At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically documented B-cell NHL (diffuse large cell, immunoblastic, anaplastic large cell, Burkitt's, or high-grade B-cell/Burkitt-like small non-cleaved)
- ✓CD20 positive tumors
- ✓Documented HIV infection by serology, culture, or quantitative PCR/bDNA assays
- ✓Evaluable or measurable disease
- ✕Prior chemotherapy or radiotherapy for this lymphoma
- ✕Primary CNS lymphoma (parenchymal brain or spinal cord tumor)
- ✕Acute active HIV-associated opportunistic infection requiring antibiotic treatment (mycobacterium avium allowed; chronic myelosuppressive therapy allowed if hematologic criteria met)
- ✕Concurrent malignancy excluding in situ cervical cancer, non-metastatic non-melanomatous skin cancer, or Kaposi's sarcoma not requiring systemic chemotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating rituximab, etoposide, and 5 other interventions for AIDS-related Diffuse Large Cell Lymphoma and 3 related conditions. Completed, enrolled 106 participants across 1 site.
Detailed Summary
This randomized phase II trial is studying how well giving combination chemotherapy together with rituximab works in treating patients with HIV-associated stage I, stage II, stage III, or stage IV non-Hodgkin's lymphoma. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Given IV
Given orally
Given IV
Correlative studies